AVITA Medical Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

AVITA Medical reported third-quarter 2026 revenue of $26.1 million, up 53% year over year and 20% sequentially, while gross margin rose 270 basis points to 84.0%. Its net loss narrowed to $6.2 million, or $0.20 per share, from $13.2 million a year earlier. The company raised its 2026 revenue guidance to $92 million–$94 million from $86 million–$89 million and reaffirmed its expectation of cash flow breakeven in the fourth quarter.